Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Parker Institute for Cancer Immunotherapy, Ludwig Collaborative and Swim Across America Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nat Commun. 2022 Sep 9;13(1):5312. doi: 10.1038/s41467-022-32738-7.
Response to immunotherapies can be variable and unpredictable. Pathology-based phenotyping of tumors into 'hot' and 'cold' is static, relying solely on T-cell infiltration in single-time single-site biopsies, resulting in suboptimal treatment response prediction. Dynamic vascular events (tumor angiogenesis, leukocyte trafficking) within tumor immune microenvironment (TiME) also influence anti-tumor immunity and treatment response. Here, we report dynamic cellular-level TiME phenotyping in vivo that combines inflammation profiles with vascular features through non-invasive reflectance confocal microscopic imaging. In skin cancer patients, we demonstrate three main TiME phenotypes that correlate with gene and protein expression, and response to toll-like receptor agonist immune-therapy. Notably, phenotypes with high inflammation associate with immunostimulatory signatures and those with high vasculature with angiogenic and endothelial anergy signatures. Moreover, phenotypes with high inflammation and low vasculature demonstrate the best treatment response. This non-invasive in vivo phenotyping approach integrating dynamic vasculature with inflammation serves as a reliable predictor of response to topical immune-therapy in patients.
免疫疗法的反应可能是多变且不可预测的。基于病理学的肿瘤表型分析将肿瘤分为“热”型和“冷”型,这种方法是静态的,仅依赖于单次单点活检中的 T 细胞浸润,导致治疗反应预测效果不佳。肿瘤免疫微环境(TiME)中的动态血管事件(肿瘤血管生成、白细胞迁移)也会影响抗肿瘤免疫和治疗反应。在这里,我们报告了一种体内的动态细胞水平 TiME 表型分析方法,该方法通过非侵入性反射共聚焦显微镜成像将炎症特征与血管特征相结合。在皮肤癌患者中,我们证明了三种主要的 TiME 表型与基因和蛋白质表达以及对 Toll 样受体激动剂免疫治疗的反应相关。值得注意的是,具有高炎症的表型与免疫刺激特征相关,而具有高血管生成的表型与血管生成和内皮失能特征相关。此外,具有高炎症和低血管生成的表型显示出最佳的治疗反应。这种将动态血管与炎症相结合的非侵入性体内表型分析方法可作为预测患者局部免疫治疗反应的可靠指标。
J Control Release. 2021-6-10
Int J Mol Sci. 2023-2-23
Biomed Eng Online. 2025-4-16
Int J Mol Sci. 2024-9-12
Curr Protoc. 2021-3
Front Cell Dev Biol. 2020-3-17
J Invest Dermatol. 2019-9-30